BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dore MP, Bibbò S, Loria M, Salis R, Manca A, Pes GM, Graham DY. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter 2019;24:e12659. [PMID: 31502382 DOI: 10.1111/hel.12659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Dore MP, Sau R, Niolu C, Abbondio M, Tanca A, Bibbò S, Loria M, Pes GM, Uzzau S. Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri. Nutrients 2022;14:2789. [DOI: 10.3390/nu14142789] [Reference Citation Analysis]
2 Jangid A, Fukuda S, Suzuki Y, Taylor TD, Ohno H, Prakash T. Shotgun metagenomic sequencing revealed the prebiotic potential of a grain-based diet in mice. Sci Rep 2022;12:6748. [PMID: 35468931 DOI: 10.1038/s41598-022-10762-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bell HN, Rebernick RJ, Goyert J, Singhal R, Kuljanin M, Kerk SA, Huang W, Das NK, Andren A, Solanki S, Miller SL, Todd PK, Fearon ER, Lyssiotis CA, Gygi SP, Mancias JD, Shah YM. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell 2021. [DOI: 10.1016/j.ccell.2021.12.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
4 Dargenio C, Dargenio VN, Bizzoco F, Indrio F, Francavilla R, Cristofori F. Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection. Medicina (Kaunas) 2021;57:733. [PMID: 34357014 DOI: 10.3390/medicina57070733] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Saviano A, Brigida M, Migneco A, Gunawardena G, Zanza C, Candelli M, Franceschi F, Ojetti V. Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin? Medicina (Kaunas) 2021;57:643. [PMID: 34201542 DOI: 10.3390/medicina57070643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
6 Karbalaei M, Keikha M. Rescue effects of Lactobacillus-containing bismuth regimens after Helicobacter pylori treatment failure. New Microbes New Infect 2021;42:100904. [PMID: 34150214 DOI: 10.1016/j.nmni.2021.100904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Li H, Xia XJ, Zhang LF, Chi JS, Liu P, Wu H, Xie XR, Tian DL, Kun KX, Gong RJ, Liu XM, Xu CX. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. Eur J Gastroenterol Hepatol 2021;32:194-200. [PMID: 32804837 DOI: 10.1097/MEG.0000000000001896] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Kim JY, Lee SY, Kim JH, Sung IK, Park HS. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Helicobacter 2020;25:e12683. [PMID: 32074663 DOI: 10.1111/hel.12683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]